Genmab stock falls amid AbbVie lawsuit

Published 24/03/2025, 13:42
© Reuters.

Investing.com -- Shares of Genmab (NASDAQ:GMAB) fell 3.8% as the biotech company faces a legal challenge from AbbVie Inc (NYSE:ABBV). AbbVie has filed a complaint in the U.S. District Court for the Western District of Washington, alleging that Genmab and other defendants misappropriated trade secrets related to antibody-drug conjugates (ADCs).

The dispute centers on the use of disaccharides to improve the hydrophilicity of drug-linkers in ADCs, particularly in relation to Genmab’s rinatabart sesutecan (Rina-S™) and other ADC pipeline products of ProfoundBio. AbbVie is seeking damages and broad injunctive reliefs, although it is not enforcing any patent rights against Genmab at this time.

Genmab has strongly denied the allegations, stating it will vigorously defend against AbbVie’s claims. The company emphasizes that this lawsuit is one of several recent cases where AbbVie has accused competitors and former employees of trade secret misappropriation. Genmab acquired ProfoundBio in May 2024, and the complaint involves Rina-S, a clinical-stage ADC currently in Phase 3 development for ovarian cancer and other solid tumors.

Despite the litigation, Genmab continues to express confidence in its scientific foundation and track record in developing antibody-based medicines. The company plans to expand the development of Rina-S based on promising clinical data. Moreover, Genmab’s collaboration with AbbVie on epcoritamab remains unaffected, with ongoing commitment to the broad clinical development and commercialization of the drug.

Genmab has stated it will not provide further comments or information on the ongoing litigation until there is a decision on the merits, a material order is issued, or the litigation concludes. The market’s reaction to the lawsuit reflects concerns over the potential impact on Genmab’s pipeline and future prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.